Back to top
more

Merck & Co. (MRK)

(Delayed Data from NYSE)

$106.34 USD

106.34
10,687,953

-2.36 (-2.17%)

Updated Oct 21, 2024 04:00 PM ET

After-Market: $106.31 -0.03 (-0.03%) 4:56 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 14% (34 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Gilead's (GILD) Breast Cancer Drug MAA Validated by EMA

by Zacks Equity Research

Gilead's (GILD) regulatory application for breast cancer drug has been validated by the regulatory body in Europe.

Bristol-Myers (BMY) Announces Results From Opdivo Combo Study

by Zacks Equity Research

Bristol-Myers (BMY) announces encouraging primary results from a study, evaluating a fixed-dose combination of relatlimab and immuno-oncology drug, Opdivo, in metastatic or unresectable melanoma.

Why Merck (MRK) is a Top Dividend Stock for Your Portfolio

by Zacks Equity Research

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.

Pfizer (PFE) Begins Clinical Study on COVID-19 Antiviral Pill

by Zacks Equity Research

Pfizer (PFE) starts an early-stage U.S. study on an oral COVID-19 antiviral candidate.

Merck (MRK) Gets FDA Nod for Keytruda in Esophageal Cancer

by Zacks Equity Research

The FDA approves Merck's (MRK) anti-PD-1 therapy, Keytruda in combination with chemotherapy, for the first-line treatment of esophageal and gastroesophageal junction carcinoma.

Merck (MRK) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

In the latest trading session, Merck (MRK) closed at $76.27, marking a -1.6% move from the previous day.

Roche's (RHHBY) Tecentriq Meets Primary Goal in Lung Cancer Study

by Zacks Equity Research

Roche's (RHHBY) Tecentriq meets primary endpoint of disease-free survival at the interim analysis in lung cancer patients.

Kinjel Shah headshot

Pharma Stock Roundup: J&J, AZN COVID-19 Update, FDA Delays Decision on ABBV's sNDA

by Kinjel Shah

WHO gives EUL to J&J's (JNJ) COVID-19 vaccine. FDA pushes back review on AbbVie's (ABBV) sNDA

Merck (MRK) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

Merck (MRK) closed the most recent trading day at $77.30, moving +0.64% from the previous trading session.

Merck (MRK) VHL-Linked Kidney Cancer Drug Gets FDA Priority Tag

by Zacks Equity Research

The FDA grants Merck's (MRK) NDA for belzutifan priority review status to treat von Hippel-Lindau disease-associated renal-cell carcinoma.

Gilead (GILD), Merck Collaborate for Long-Acting HIV Treatments

by Zacks Equity Research

Gilead (GILD) collaborates with Merck for developing long-acting treatments for HIV patients.

Lilly (LLY) Down as Alzheimer's Drug Fails Investor Expectation

by Zacks Equity Research

Eli Lilly (LLY) announces detailed data on secondary endpoints of its mid-stage study evaluating its antibody candidate, donanemab, in patients with early symptomatic Alzheimer's disease.

Corcept (CORT) Begins Adrenal Cancer Study on Relacorilant

by Zacks Equity Research

Corcept (CORT) commences phase Ib study on relacorilant in combination with Keytruda for treating patients with adrenal cancer with cortisol excess.

AVEO Collaborates with Bristol Myers to Conduct Combo Study

by Zacks Equity Research

AVEO forges an alliance with Bristol Myers to evaluate Fotivda in combination with Opdivo for RCC.

Sweta Killa headshot

Air Travel Demand Nears 1-Year High: ETFs to Fly High

by Sweta Killa

According to the latest data from Transportation Security Administration (TSA), about 1.357 million travelers checked in at American airports on Mar 12 - the highest number since Mar 15, 2020.

J&J (JNJ) COVID-19 Vaccine Gets WHO's Emergency Listing

by Zacks Equity Research

J&J's (JNJ) single-shot COVID-19 vaccine gets Emergency Use Listing by the WHO, which will enable it to supply its vaccine to over 190 countries through COVAX facility.

The Zacks Analyst Blog Highlights: Netflix, Toyota, AbbVie, Merck and Sinopec

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Netflix, Toyota, AbbVie, Merck and Sinopec

Mark Vickery headshot

Top Stock Reports for Netflix, Toyota & AbbVie

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including Netflix (NFLX), Toyota Motor (TM), and AbbVie (ABBV).

Kinjel Shah headshot

Pharma Stock Roundup: EU Nod for J&J COVID-19 Vaccine, Updates From LLY, GSK, MRK

by Kinjel Shah

Europe clears J&J's (JNJ) COVID-19 vaccine. Eli Lilly (LLY), Merck (MRK) and Glaxo (GSK) give update on their COVID-19 antibody/antiviral candidates.

Merck (MRK) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Merck (MRK) closed at $74.63 in the latest trading session, marking a -0.17% move from the prior day.

Mark Vickery headshot

Dow Hits New All-Time High Close as Rescue Bill Passes

by Mark Vickery

Expectations are now for a full-throated economic recovery to take hold, which happens to be dovetailing with the reopening of around a dozen states.

This is Why Merck (MRK) is a Great Dividend Stock

by Zacks Equity Research

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.

Novartis' (NVS) NSCLC Drug Fails to Meet Primary Endpoint

by Zacks Equity Research

Novartis (NVS) pipeline candidate, canakinumab, fails to meet the primary endpoint in lung cancer study.

Roche (RHHBY) Withdraws Bladder Cancer Indication for Tecentriq

by Zacks Equity Research

Roche (RHHBY) voluntarily withdraws the bladder cancer indication of Tecentriq in the United States.

Sweta Jaiswal, FRM headshot

Momentum ETFs to Gain From the New Stimulus Optimism

by Sweta Jaiswal, FRM

Here we highlight some momentum ETFs that are lucrative investment picks keeping in mind the optimism surrounding Wall Street.